Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein overexpressed in various cancers, promoting cell proliferation.
• The role of CIP2A in glioblastoma multiforme (GBM) and its potential as a drug target remain largely unexplored.

Purpose of the Study:

• To investigate the role of CIP2A in GBM invasive behavior.
• To evaluate the anti-cancer effects of cucurbitacin B (CuB) in GBM.
• To explore the therapeutic potential of targeting CIP2A in GBM treatment.

Main Methods:

• GBM cell lines were treated with CuB.
• Overexpression and silencing of CIP2A were performed in GBM cells.
• Western blot analysis was used to assess protein levels (CIP2A, phospho-Akt) and PP2A activity.
• In vivo tumor growth inhibition in murine models was evaluated.

Main Results:

• Overexpression of CIP2A enhanced GBM cell invasion.
• CuB exhibited anti-proliferative and anti-invasion effects in GBM cells by inducing apoptosis, downregulating CIP2A and phospho-Akt, and upregulating PP2A activity.
• Silencing CIP2A potentiated CuB's anti-cancer effects, while CIP2A overexpression diminished them.
• CuB demonstrated synergistic effects with cisplatin and inhibited tumor growth in vivo.

Conclusions:

• CIP2A inhibition is crucial for CuB's anti-invasive and pro-apoptotic effects in GBM.
• CuB is a promising therapeutic candidate for GBM, warranting further development and the design of novel CIP2A inhibitors.